PE anti-mouse IL-1α Antibody
- 产品名称：
- PE anti-mouse IL-1α Antibody
- 产品类别：
- 抗体
- 产品编号：
- 503203
- 产品应用：
- 503203
- Verified Reactivity
- Mouse
- Antibody Type
- Monoclonal
- Host Species
- Armenian Hamster
- Immunogen
- E. coli - expressed, recombinant mouse IL-1
- Formulation
- Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
- Preparation
- The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
- Concentration
- 0.2 mg/ml
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
- Application
-
ICFC - Quality tested
- Recommended Usage
Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 1.0 ?g per million cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.
- Excitation Laser
- Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
- Application Notes
ELISA or ELISPOT Capture: The purified ALF-161 antibody is useful as the capture antibody in a sandwich ELISA or ELISPOT assay, when used in conjunction with the biotinylated Poly5034 antibody (Cat. No. 503401) as the detecting antibody. The Ultra-LEAF? purified antibody is suggested for ELISPOT capture.
ELISA Capture: The purified ALF-161 antibody is useful as the capture antibody in a sandwich ELISA when used in conjunction with the biotinylated BL1a-89 antibody (Cat. Nos. 512503 & 512504) as the detection antibody and recombinant mouse IL-1a (Cat. No. 580309) as the standard.
Neutralization: Clone ALF-161 has been described to have IL-1a neutralizing properties based on the in vivo mice model3. The Ultra-LEAF? purified antibody (Endotoxin <0.01 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended (Cat. No. 503207-503212).
- Application References
(PubMed link indicates BioLegend citation) -
- Fuhlbrigge R, et al. 1988. J. Immunol. 141:2643.
- Rogers HW, et al. 1992. P. Natl. Acad.Sci. USA 89:1011.
- Yazdi AS, et al. 2010. P. Natl. Acad. Sci. USA 107:19449. (Neut)
- Product Citations
-
- Laura C Burzynski et al. 2019. Immunity. 50(4):1033-1042 . PubMed
- Cullis J, et al. 2017. Cancer Immunol Res. 5:182. PubMed
- Wei H, et al. 2021. Malar J. 20:89. PubMed
- Tilstam PV, et al. 2021. J Clin Invest. 131:. PubMed
- Nakagawa S et al. 2017. Cell host & microbe. 22(5):667-677 . PubMed
- Ratitong B, et al. 2021. Cell Reports. 35(7):109139. PubMed
- Chryplewicz A, et al. 2022. Cancer Cell. 40:1111. PubMed
- RRID
- AB_315281 (BioLegend Cat. No. 503203)
- Structure
- Cytokine; 17.4 kD (Mammalian)
- Bioactivity
- Stimulates T cells, B cells, proliferation/activation of NK cells, fibroblasts, thymocytes, glioblastoma cells, astroglia, microglia; monocyte transition from IL-1β to IL-1α when matured to macrophages
- Cell Sources
- Monocytes, tissue macrophages, Langerhan cells, dendritic cells, T lymphocytes, B lymphocytes, natural killer (NK) cells, large granular lymphocytes (LGL), vascular endothelium, smooth muscle, fibroblasts, thymic epithelia, astrocytes, microglia, glioma,
- Cell Targets
- B cells, T cells, monocytes, fibroblasts
- Receptors
- Type I IL-1R (CDw121a), Type II IL-1R (CDw121b)
- Biology Area
- Immunology, Innate Immunity
- Molecular Family
- Cytokines/Chemokines
- Antigen References
-
1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press San Diego.
2. Bomford R, et al. Eds. 1989. Interleukin-1 inflammation and disease. Elsevier New York.
3. Brazel D, et al. 1991. Biotechnol. Ther. 2:241.
4. Dinarello C. 1996. Blood 87:2095.
- Regulation
- Upregulated by TNF-α, IFN-α, IFN-β, IFN-γ, bacterial endotoxins, viruses, mitogens, antigens; downregulated by IL-6, lipoproteins, lipids, and α2-macroglobulin
- Gene ID
- 16175 View all products for this Gene ID
- UniProt
- View information about IL-1alpha on UniProt.org
